Rasburicase: a potent uricolytic agent

Expert Opinion on Pharmacotherapy
Ching-Hon Pui

Abstract

Rasburicase (Fasurtec, Elitek, Sanofi-Synthelabo) is a new recombinant urate oxidase developed for the prevention and treatment of hyperuricaemia. It has a half-life of 17-21 h and produces rapid (within 4 h) and pronounced reductions in plasma uric acid concentrations. To date, rasburicase has been tested in four clinical trials conducted in patients with cancer (primarily haematological malignancies). It successfully alleviated hyperuricaemia in 98% of patients and prevented this complication in 99.6% of those who were at risk. In a stratified, randomised trial, rasburicase was more effective than allopurinol. Most patients had improved or stabilised renal function during rasburicase treatment, despite ongoing chemotherapy-induced tumour lysis. Except for occasional instances of haemolytic anaemia and methemoglobinaemia in patients with glucose-6-phosphate dehydrogenase deficiency, rasburicase was well-tolerated, with a low frequency of mild adverse events. Rasburicase is a safe and effective agent in the prevention or treatment of hyperuricaemia in cancer patients.

References

Nov 1, 1976·The Journal of Pediatrics·R H Yolken, D R Miller
Jan 1, 1992·Cytogenetics and Cell Genetics·A V YeldandiM M Le Beau
Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·X W WuC T Caskey
Mar 1, 1974·Archives of Internal Medicine·C M KjellstrandT J Buselmeier
Dec 20, 1973·The New England Journal of Medicine·J ZusmanM E Nesbit
Mar 1, 1968·The Journal of Pediatrics·P Holland, N H Holland
Aug 13, 1970·The New England Journal of Medicine·P R BandA S Little
Feb 20, 1969·The New England Journal of Medicine·M L GreeneJ E Seegmiller
Jul 1, 1966·Biochemical Pharmacology·G B ElionG H Hitchings
Jan 1, 1982·The Journal of Pediatrics·G MaseraM Recchia
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W P BowmanS Murphy
Jul 29, 1998·Clinical and Laboratory Haematology·M LeachD A Winfield
Nov 16, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·G WolfR A Stahl
Apr 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R V SmalleyJ A Hohneker
Jul 25, 2000·Journal of the American Society of Nephrology : JASN·Abhijit V KshirsagarRonald J Falk
Jul 5, 2001·Paediatric Drugs·J EastonB Jarvis
Apr 1, 1965·Annals of Internal Medicine·J R KLINENBERGJ E SEEGMILLER

❮ Previous
Next ❯

Citations

Apr 6, 2012·Current Hematologic Malignancy Reports·Adele K FieldingDavid I Marks
Aug 29, 2003·Current Opinion in Biotechnology·Michel Vellard
Mar 6, 2010·Journal of Neuroinflammation·Denise HarhausenGeorge Trendelenburg
Mar 31, 2007·International Journal of Medical Sciences·Lisa Cammalleri, Mariano Malaguarnera
Jul 26, 2014·Emergency Medicine Clinics of North America·Jonathan Wagner, Sanjay Arora
Jun 7, 2006·Leukemia & Lymphoma·Scott C Howard, Ching-Hon Pui
Mar 1, 2006·Expert Review of Anticancer Therapy·John Gerecitano, David J Straus
Jul 17, 2008·Supportive Cancer Therapy·G Kesava ReddyJeffrey Crawford
Dec 1, 2009·Critical Care Clinics·Deepti BehlTimothy J Moynihan
May 16, 2012·Critical Care Medicine·Michael T McCurdy, Carl B Shanholtz
Jul 17, 2008·Supportive Cancer Therapy·Anne-Sophie MichalletBertrand Coiffier
Sep 18, 2007·Advanced Drug Delivery Reviews·Gianfranco PasutFrancesco M Veronese
May 24, 2006·Rheumatic Diseases Clinics of North America·Nancy Joseph-RidgePatricia MacDonald
Sep 24, 2004·British Journal of Haematology·Mitchell S Cairo, Michael Bishop
Dec 17, 2008·Cancer Science·Kenichi IshizawaYasuo Morishima
Apr 20, 2011·Journal of Clinical Pharmacy and Therapeutics·P Bose, O Qubaiah
May 11, 2011·British Journal of Haematology·Andrew Will, Eleni Tholouli
Feb 15, 2005·Clinical Biochemistry·Ken-Shwo DaiSimon J T Mao
Feb 18, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Albert C YehBimalangshu R Dey
Jan 13, 2015·Cellular Oncology (Dordrecht)·Chiara PesentiMonica Miozzo
Jan 9, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Katherine C AllenSteven M Trifilio
May 3, 2014·Clinical Pharmacology and Therapeutics·M V RellingUNKNOWN Clinical Pharmacogenetics Implementation Consortium
Dec 2, 2004·Nucleosides, Nucleotides & Nucleic Acids·J M de Bont, R Pieters
Aug 5, 2004·The Annals of Pharmacotherapy·Tamra M ArnoldCarl B Shanholtz
Oct 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bertrand CoiffierUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma
Jun 9, 2017·PloS One·Paulina SzczurekKateryna Goncharova
Nov 26, 2003·Current Opinion in Critical Care·Norbert H LameireRaymond Vanholder
Aug 17, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Mary NauffalAnne M McDonnell
Jan 26, 2012·Expert Review of Hematology·Giulia MalaguarneraMariano Malaguarnera
Jun 11, 2014·Pharmacogenetics and Genomics·Ellen M McDonaghTeri E Klein
Nov 28, 2019·British Journal of Haematology·Urshila Durani, William J Hogan
Jul 26, 2003·Clinical Chemistry·EeMun LimJohn Beilby

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.